Urologic Oncology: Seminars and Original Investigations

Title Publication Date Language Citations
HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer2006/05/01English64
Plasma microRNA profiles for bladder cancer detection2013/11/01English64
Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis2014/02/01English64
Metastatic renal cell carcinoma: Patterns and predictors of metastases—A contemporary population-based series2017/11/01English63
Target detection: Magnetic resonance imaging-ultrasound fusion–guided prostate biopsy2014/08/01English63
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer2009/03/01English63
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer☆2005/11/01English63
The evolution of bladder cancer genomics: What have we learned and how can we use it?2018/07/01English62
Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity–focused ultrasound focal therapy for localized prostate cancer2017/01/01English62
Bladder cancer risk from occupational and environmental exposures2012/03/01English61
Differential ectonucleotidase expression in human bladder cancer cell lines2010/05/01English61
Changes in epidemiologic features of testicular germ cell cancer: Age at diagnosis and relative frequency of seminoma are constantly and significantly increasing2014/01/01English61
Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature2014/05/01English61
Urine microRNAs as potential noninvasive biomarkers in urologic cancers2014/01/01English61
Contemporary bladder cancer: Variant histology may be a significant driver of disease2015/01/01English61
Endoscopic treatment of upper tract transitional cell carcinoma2005/03/01English61
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy2012/05/01English60
Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model2009/07/01English60
Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma2014/10/01English60
A prospective comparison of the pathologic and surgical outcomes obtained after elective treatment of renal cell carcinoma by open or robot-assisted partial nephrectomy2013/08/01English59
Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment2019/06/01English59
The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy2017/05/01English59
Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma2013/11/01English58
MicroRNA expression profiles in the progression of prostate cancer—from high-grade prostate intraepithelial neoplasia to metastasis2013/08/01English58
Improved prostate cancer detection with anterior apical prostate biopsies2006/11/01English58
Surgical benchmarks for the treatment of invasive bladder cancer2007/01/01English58
Lycopene as a chemopreventive agent in the treatment of high-grade prostate intraepithelial neoplasia2005/11/01English58
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer2013/01/01English58
Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non–muscle-invasive bladder cancer2015/02/01English58
Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab2019/06/01English57